The Wrong Metric
When Mass Matters Less Than Particle Count
TL;DR (The Quick Version)
In February 2025, researchers at the University of New Mexico published one of the most widely reported findings in environmental science: human brains contain approximately 5,000 micrograms of plastic per gram of brain tissue - roughly 0.5% of brain weight, or about a plastic spoon’s worth of nanoplastic shards in your prefrontal cortex.
That concentration had increased 50% in just eight years, from 2016 to 2024.
In April 2026, a different research team published a different study of brain tissue - this time from living surgical patients with brain tumors - and found a much lower figure: approximately 50 micrograms per gram. About 100 times less.
The headlines wrote themselves. “Microplastics found in 100% of brains, but far less than RFK Jr. claim.” HHS Secretary Kennedy had cited the spoonful figure publicly. The new study appeared to correct him. A quiet sigh of relief was exhaled.
This signal is about why that sigh is the wrong response.
The two studies used different methodologies, different patient populations, different brain tissue types, and different detection approaches. They are not a correction of each other. They are two data points in a field that urgently needs better measurement tools - a fact the U.S. government just acknowledged with a $144 million research program launched the same month.
More importantly: the April 2026 study that produced the “reassuringly lower” mass figure also found something the headlines buried. Its own researchers, when looking for what actually predicts harm in brain tissue, did not use mass as their metric.
They used surface area.
Microplastic surface area correlated positively with tumor proliferation. Not mass. Surface area. The same study producing the “less than we thought” headline independently confirmed that mass is the wrong metric for evaluating biological risk.
This signal explains why that matters - and why the entire public debate may be structured around a measurement that systematically understates the danger as the contamination ages and fragments.
THE TWO STUDIES: WHAT THEY ACTUALLY SHOW
THE NIHART STUDY (February 2025):
Nihart et al., “Bioaccumulation of microplastics in decedent human brains,” Nature Medicine, Vol 31, pp. 1114-1119.
Lead institution: University of New Mexico Health Sciences.
Population: Post-mortem decedents. Autopsy samples obtained through the UNM Office of the Medical Investigator in Albuquerque.
28 brain samples from 2016, 24 from 2024.
Methodology: Three complementary analytical techniques - Pyrolysis gas chromatography-mass spectrometry (Py-GC/MS), attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR), and electron microscopy with energy-dispersive spectroscopy (EDS).
Key findings:
MNPs confirmed in every brain sample.
Brain contained up to 30 times more MNPs than liver or kidney from the same individual.
Approximately 5,000 micrograms per gram of brain tissue in 2024 samples - 0.5% by weight.
50% increase from 2016 to 2024.
Predominant polymer: polyethylene.
Particle character: “largely nanoscale shard-like fragments,” predominantly under 200 nm length, 40 nm width.
Three to five times greater accumulation in dementia patients versus cognitively normal controls.
Lead researcher Dr. Matthew Campen: “There’s much more plastic in our brains than I ever would have imagined or been comfortable with.”
THE LI ET AL. STUDY (April 2026):
Li R. et al., “Microplastics and nanoplastics in brain tumours and the healthy human brain,” Nature Health, April 20, 2026. DOI: 10.1038/s44360-026-00091-4
Population: 113 living patients undergoing brain tumor surgery (156 diseased brain samples) and 5 post-mortem donors (35 healthy brain samples). Total: 191 brain samples.
Methodology: Different detection approach from Nihart - specifically designed to address concerns about Py-GC/MS lipid interference that had been raised in the Matters Arising critique of the earlier study.
Key findings:
MNPs present in 99.4% of diseased brain samples.
MNPs present in 100% of healthy brain samples.
Average concentration: approximately 50 micrograms per gram of brain tissue - roughly 100 times lower than Nihart.
Higher MNP concentration in peritumoural tissue than in healthy tissue - compromised blood-brain barrier in cancer appears to increase MNP entry.
POSITIVE CORRELATION BETWEEN MICROPLASTIC SURFACE AREA AND TUMOR PROLIFERATION.
The study authors: “highlighting a need for further research to understand causal links between MNPs and human disease.”
WHY THESE ARE NOT A SIMPLE CORRECTION OF EACH OTHER:
The headlines framed the Li et al. finding as a correction of Nihart - the real number is lower than the scary number. This framing is incorrect for several reasons.
Different populations: Nihart studied post-mortem decedents. Li et al. studied living surgical patients with brain tumors plus a small post-mortem sample. These populations are not equivalent. Brain tumor patients may have different MNP accumulation dynamics due to compromised BBB. The study itself notes that BBB disruption in cancer “may aid MNP entry” - meaning the tumor patient samples may actually skew higher than general population, not lower.
Different brain regions: The studies analyzed different regions of brain tissue. MNP accumulation is not uniform across brain structures. Comparing region-specific measurements across studies is not an apples-to-apples comparison.
Different methodologies: The studies used different detection approaches. As ARPA-H’s own STOMP program launch acknowledged in April 2026: “we don’t have a precise way to measure microplastics in our organs.”
Both studies are doing their best with available tools. Neither is the definitive figure.
The honest scientific position: we have two studies producing different mass figures using different methods on different populations studying different brain regions. The correct response is better measurement infrastructure - which is exactly what $144 million of federal funding was just allocated to develop. Not “it’s less than we thought, therefore safer.”
And then there is the surface area finding. Which changes everything about how to read both studies.
THE SURFACE AREA FINDING: THE HEADLINE WITHIN THE HEADLINE
Buried in the Li et al. April 2026 study - the one generating the “far less than RFK claimed” coverage - is a finding that received almost no mainstream attention.
The researchers did not find that MNP mass correlated with tumor proliferation. They found that MNP surface area correlated with tumor proliferation.
Read that again slowly.
The research team studying whether brain MNPs are associated with cancer growth chose surface area as their analytical metric - not mass - and found a statistically significant positive correlation.
This is not a rhetorical point made by a science communicator. This is the finding of the peer-reviewed study itself. The scientists who produced the “reassuringly lower” mass figure simultaneously confirmed, in the same paper, that surface area is the biologically meaningful metric.
Surface area is determined by particle count and particle size - not by mass alone. A given mass of nanoplastics has orders of magnitude more surface area than the same mass in larger microplastic form.
The study found lower mass. The study also found that mass is not what predicts harm.
Both findings appeared in the same paper on the same day.
One made headlines. One did not.
THE WRONG METRIC: WHY MASS FAILS AS A RISK MEASURE
The biological damage from MNPs does not scale with mass. It scales with particle count, particle size, and surface area.
This is not a rhetorical position. It follows directly from the mechanisms by which MNPs cause damage.
SURFACE AREA AND CHEMICAL LEACHING:
MNPs leach chemical additives - plasticizers, flame retardants, UV stabilizers, heavy metals, adsorbed PFAS - from their surfaces into surrounding tissue. The rate of leaching is proportional to surface area, not mass.
Consider two hypothetical samples with identical plastic mass:
SAMPLE A: 100 particles, average size 1 millimeter
Total surface area: X
SAMPLE B: 100 billion particles, average size 1 nanometer
Total surface area: approximately 1 billion times X
Same mass. One billion times the surface area. One billion times the chemical leaching interface. One billion times the contact surface for toxic additive release directly into brain tissue.
The smaller the particles, the greater the surface area per unit mass. Nanoplastics - confirmed as the predominant form in both brain studies - represent the extreme end of this surface area amplification. When mass measurements decrease because better methodology is distinguishing nanoplastics more precisely, the biological activity per unit mass may actually be increasing.
PARTICLE COUNT AND CELLULAR DISRUPTION:
Every particle that crosses a cellular boundary - the blood-brain barrier, a neuronal cell membrane, a mitochondrial membrane, a nuclear membrane - is an individual physical event causing individual physical disruption.
The BBB crossing is not a mass phenomenon. It is a particle phenomenon. What scales with particle count:
Number of BBB crossing events and barrier disruption
Number of neuroinflammatory responses triggered
Number of mitochondrial interactions
Number of cellular membrane penetrations
Number of protein aggregation seeds (relevant to Parkinson’s, Alzheimer’s, and dementia pathology)
SUBCELLULAR ACCESS - THE QUALITATIVE THRESHOLD:
This is the threshold mass measurement completely obscures.
Particles larger than approximately 1 micrometer cannot cross the blood-brain barrier under normal conditions. They cannot enter cells. They cannot access mitochondria or nuclei.
Particles smaller than 1 micrometer - nanoplastics - can cross the BBB. Can enter cells. Can access organelles. Can interact directly with DNA.
These two populations are not just quantitatively different. They are qualitatively different in their biological impact.
The Nihart electron microscopy found brain particles are “largely nanoscale shard-like fragments” predominantly under 200 nm. The Li et al. study confirmed nanoplastic-scale particles in both healthy and tumor tissue.
These are in the subcellular access range. Their biological activity scales with count and surface area - not mass.
A lower mass figure dominated by nanoplastics at high particle count is not reassuring. It may be the more alarming scenario.
THE FRAGMENTATION TRAJECTORY:
Plastic in the environment does not stay at its original size. UV exposure, mechanical stress, biological degradation, and weathering continuously break plastic into smaller particles. The direction of travel is always toward smaller.
This means a given mass of environmental plastic becomes more particles over time, not fewer. More surface area. More biological activity. More subcellular access. More damage per unit mass, not less, as time passes.
Mass stays roughly constant. Particle count increases. Average size decreases. Surface area increases. Biological risk profile intensifies.
A metric that tracks mass alone captures none of this trajectory. It would show stable or even decreasing mass while particle count and biological activity continue rising. Mass is not just an incomplete metric. It is a metric that systematically understates risk as the contamination ages and fragments.
THE THREE CONDITIONS THAT DON’T DEPEND ON MASS
Regardless of the precise mass figure - whether 5,000 micrograms per gram or 50 micrograms per gram or any corrected figure that emerges from better methodology - three conditions hold that the mass debate does not touch:
CONDITION 1: ANY PRESENCE IS SIGNIFICANT.
The blood-brain barrier exists for a reason. It is one of the most selective biological boundaries in the human body, evolved over hundreds of millions of years to protect neural tissue from chemical and particulate intrusion.
Both studies agree: MNPs are crossing it. In 99.4% to 100% of samples studied. The precise mass is secondary. “Any” is already the alarming number when the substance has no business being in brain tissue at all.
Ecotoxicologist Bethanie Carney Almroth, University of Gothenburg, on the Nihart findings: “The blood-brain barrier is not as protective as we’d like to think. Some of the particles appeared to be too big to make it into the brain, or even the blood. Yet there they are.”
CONDITION 2: THE TRAJECTORY IS UPWARD.
The Nihart study found a 50% increase in eight years using internally consistent methodology across both time points. Even if the absolute figure is revised by better tools, the trend comparison - same methodology, same lab, 2016 vs 2024 - remains valid as a directional indicator.
Global plastic production continues to increase. Environmental MNP accumulation continues to increase. The EPA just added MNPs to its Drinking Water Contaminant Candidate List for the first time in April 2026, acknowledging the contamination trajectory. Whatever the correct absolute number is today, it will be higher in eight more years.
CONDITION 3: THE PARTICLES ARE GETTING SMALLER.
Environmental fragmentation is a one-way process on human timescales. The nanoplastic proportion of total environmental MNP load is increasing. Both brain studies confirm that the particles found in human brain tissue are already in the nanoscale range - the most biologically active category.
As the environmental load shifts further toward nanoplastics, the mass-to-biological-activity ratio continues to shift unfavorably. A lower mass measurement does not mean lower risk if what remains is smaller, more numerous, and more biologically active per unit mass.
THE GOVERNMENT JUST CONFIRMED THE MEASUREMENT PROBLEM
On April 2, 2026 - eighteen days before the Li et al. study was published - ARPA-H (Advanced Research Projects Agency for Health), an agency within HHS, announced the STOMP program:
Systematic Targeting Of MicroPlastics. A $144 million initiative to develop tools to map, measure, and reduce MNP contamination in the human body.
The ARPA-H announcement states directly: “We don’t have a precise way to measure microplastics in our organs, nor do we understand which ones are affecting us in what ways - because each plastic works differently. We can’t clear what we can’t measure.”
ARPA-H Director Alicia Jackson: “Microplastics are in every organ we look at - in ourselves and in our children. But we don’t know which ones are harmful or how to remove them.”
The U.S. government just allocated $144 million explicitly because the measurement tools are inadequate. The scientific establishment - not the Nightwatchman, not alarmist commentary, but ARPA-H - has formally acknowledged that we cannot currently measure brain MNPs with sufficient precision to characterize the risk.
This is the context in which “far less than thought” headlines should be read. We are in a period of profound measurement uncertainty. Two well-designed studies using different methods on different populations produced figures 100 times apart. The government response to this uncertainty was not “therefore it’s safe” - it was $144 million to develop better tools.
The “less than we thought” headline is not a scientific conclusion. It is a measurement artifact in a field that has formally acknowledged it does not yet have the tools to measure correctly.
THE STOMP PROGRAM: WHAT BETTER MEASUREMENT SHOULD TRACK
The STOMP program’s stated goals include measurement, mechanism understanding, and eventually removal of MNPs from the human body.
Phase one focuses on measurement and mapping. If the Nightwatchman framework could submit a request for the measurement agenda, it would look like this:
PARTICLE COUNT PER UNIT TISSUE: How many individual particles are present per gram of brain tissue? This is the measurement the cancer correlation study used implicitly when it chose surface area - you cannot calculate surface area without knowing particle count and size distribution.
SIZE DISTRIBUTION DATA: What fraction of brain-resident MNPs is in each size category? What proportion is in the subcellular access range below 1 micrometer? This is the data that would allow meaningful risk characterization.
SURFACE AREA CALCULATIONS: Total surface area per unit tissue, derived from count and size distribution. The Li et al. cancer correlation study showed this is the metric that predicts biological harm. It should be the primary reported metric in all future MNP brain research.
CHEMICAL CHARACTERIZATION OF LEACHATE: What additives and adsorbed contaminants are actually being released from brain-resident MNPs into neural tissue? The particles are not the only danger - they are also delivery vehicles for plasticizers, flame retardants, PFAS, and other toxins.
LONGITUDINAL PARTICLE COUNT TRENDS: Not mass change over time - particle count and size distribution change over time. Is the same mass arriving as fewer larger particles (less concerning) or more smaller particles (more concerning)?
These measurements would answer the questions that actually matter. The current mass debate is a debate about the wrong quantity.
THE INDUSTRY PLAYBOOK: WHAT’S COMING
The methodological debate between the Nihart and Li et al. studies is legitimate science. Studies challenging each other’s findings and methods is how the field advances.
What is not legitimate is the use of measurement uncertainty to imply safety.
The tobacco industry spent decades arguing that the precise mechanism of cancer causation was not established - which was true at various points - while using that uncertainty to block action on a product they knew was killing people.
The argument from scientific uncertainty, deployed in service of commercial interest, is a documented and replicable playbook.
The plastics industry response to the Nihart study is already visible. The American Chemistry Council: the industry is “dedicated to advancing the scientific understanding of microplastics.” The FDA: “current scientific evidence does not demonstrate that levels of microplastics or nanoplastics detected in foods pose a risk to human health.”
Note the FDA statement’s structure. It does not say MNPs are safe. It says current evidence does not demonstrate risk at detected levels. This is a mass-based threshold argument: the detected levels (mass) are not yet proven harmful at current measurements. As this signal has argued, mass is the wrong metric for that threshold.
The “less than we thought” headline will be deployed. It is already appearing in coverage. The structure of its misuse:
STEP 1: Cite the Li et al. 50 micrograms figure.
STEP 2: Compare to the Nihart 5,000 micrograms figure.
STEP 3: Declare the earlier concern was 100x exaggerated.
STEP 4: Imply the risk is proportionally 100x smaller.
STEP 5: Continue plastic production and use as before.
Every step of this argument has a response:
STEP 1 RESPONSE: The Li et al. study used different methods on a different population studying different brain regions. It is not a correction. It is a second data point in a field that needs better tools.
STEP 2 RESPONSE: Comparing these figures as if they measure the same thing in the same way is methodologically invalid.
STEP 3 RESPONSE: The government just spent $144 million acknowledging we cannot currently measure MNPs in organs with sufficient precision. Neither figure is “the number.”
STEP 4 RESPONSE: This assumes mass predicts risk. The Li et al. study itself found surface area - not mass - correlates with tumor proliferation. The biological risk does not scale with mass. It scales with particle count, surface area, and subcellular access.
STEP 5 RESPONSE: Both studies found MNPs in 100% of healthy brains. Both found levels are increasing. Both found particles in the nanoscale range with subcellular access potential.
The three conditions that matter - presence, trajectory, fragmentation - are unaffected by the mass debate.
This signal exists to make that response available before the playbook deploys at scale. The time to establish the correct analytical framework is before the industry talking points have taken hold in public consciousness, not after.
THE DISEASE CORRELATIONS: INDEPENDENT OF MASS
The neurological disease correlations documented in MNP brain research do not depend on any particular mass figure:
DEMENTIA: The Nihart study found three to five times greater MNP accumulation in dementia patients versus cognitively normal controls. This is a correlation, not proven causation - but a three to five times enrichment is not noise. The mass debate does not affect this ratio, which is an internal comparison using consistent methodology.
PARKINSON’S DISEASE: A 2026 review in npj Parkinson’s Disease, drawing on more than 100 published studies, concluded that emerging evidence suggests MNPs may be contributing to the increase in Parkinson’s disease, which has doubled in prevalence over the past 25 years. The proposed mechanism: MNP-induced aggregation of misfolded alpha-synuclein - the defining pathological hallmark of Parkinson’s. This mechanism is driven by particle-surface interaction, not mass.
BRAIN TUMORS: The Li et al. study - the “reassuringly lower” mass study - found a positive correlation between MNP surface area and tumor proliferation across 156 diseased brain samples.
Surface area. Not mass.
Three serious neurological conditions. Three independent research groups. Three consistent directional signals. All pointing toward MNP accumulation in brain tissue as a potential contributor to pathological outcomes. None of these correlations require any particular mass figure to hold.
What dementia, Parkinson’s, brain tumor proliferation, and the cognitive/behavioral signals documented across this series have in common: they all involve the prefrontal cortex, the hippocampus, the dopaminergic pathways, and mitochondrial integrity of neurons. The same structures. The same systems.
The brain accumulates more plastic than any other organ. The particles are nanoscale shards. They are increasing. The diseases they correlate with are the diseases this series has been documenting as accelerating.
The question is not how many grams.
The question is what those shards are doing in there.
And on that question, the evidence - independent of mass - is consistently alarming.
THE HONEST LIMITS
This signal argues that mass is the wrong metric. That argument should be held to the same epistemic standard as everything else in this series.
WHAT IS ESTABLISHED:
MNPs are present in human brain tissue. Both studies confirm.
The concentration is increasing over time (Nihart, 50% in 8 years, internally consistent methodology).
The particles are predominantly nanoscale with subcellular access potential. Both studies confirm.
Surface area correlates with tumor proliferation in brain tissue. Li et al. confirm.
The field lacks adequate measurement tools. ARPA-H/STOMP confirms with $144 million in funding.
MNP brain accumulation correlates with dementia (Nihart), Parkinson’s mechanisms (2026 review), and tumor growth (Li et al.).
WHAT IS NOT ESTABLISHED:
The precise mass, particle count, or surface area of MNPs in the general population’s brain tissue. Both figures - 5,000 and 50 micrograms per gram - have methodological limitations. The true figure is unknown.
Direct causation between brain MNP accumulation and any specific neurological disease. All correlations remain associations requiring further investigation.
The specific biological threshold at which brain MNP accumulation produces functional harm in humans.
Whether current exposure levels are above or below any such threshold.
WHAT THIS SIGNAL CLAIMS:
Mass is the wrong metric for risk evaluation, based on the established biology of how MNPs cause damage.
The three conditions of concern - presence, trajectory, fragmentation - are unaffected by the mass debate.
The “less than we thought” framing, if used to imply reduced concern, is analytically incorrect.
Better measurement infrastructure, structured around particle count and surface area rather than mass, is urgently needed. The government agrees.
The Nightwatchman framework does not claim to know the precise risk. It claims that the framework being used to evaluate the risk - mass-based measurement and mass-based thresholds - is systematically inadequate, and that the inadequacy runs in a direction that understates concern rather than overstates it.
That claim is supported by the biology, by the Li et al. surface area finding, and by the U.S. government’s $144 million acknowledgment that we cannot currently measure what matters.
THE CONNECTIONS
This signal occupies a unique methodological position in the framework. It is not documenting a new harm. It is arguing that the existing harms are being systematically mismeasured in a way that produces false reassurance.
Signal #18 (The Hidden Plastic Cloud) established that atmospheric MNP concentrations were orders of magnitude higher than previously measured - a systematic underestimate in the other direction. The MNP field has a pattern of underestimation that consistently runs toward “less dangerous than it actually is.” The mass debate is potentially adding another chapter to that pattern.
The cognitive decline signals document the PFC, hippocampus, and dopaminergic pathways as primary targets of MNP neurotoxicity. The dementia correlation in the Nihart study, the Parkinson’s mechanism in the npj review, and the tumor proliferation correlation in Li et al. all implicate overlapping neural architecture. The mass debate does not change this convergence.
The STOMP program’s launch represents something new in this series: formal U.S. government acknowledgment that MNPs are in every organ including the brain, that the measurement tools are inadequate, and that the problem is serious enough to warrant urgent, large-scale federal research investment.
The Nightwatchman framework has been making this argument from the margins for months. The government just moved it to the center - and confirmed, in the process, that the measurement problem this signal identifies is real.
We can’t clear what we can’t measure. We can’t measure what we’re measuring incorrectly.
And mass, for reasons this signal has laid out in detail, is the wrong thing to measure.
SOURCES
PRIMARY STUDIES:
Nihart AJ et al., “Bioaccumulation of microplastics in decedent human brains,” Nature Medicine, February 2025, Vol 31, pp. 1114-1119. DOI: 10.1038/s41591-024-03453-1. [5,000 mcg/g, 0.5% by weight, 50% increase 2016-2024, 3-5x enrichment in dementia, nanoscale shards confirmed by electron microscopy]
Li R. et al., “Microplastics and nanoplastics in brain tumours and the healthy human brain,” Nature Health, April 20, 2026. DOI: 10.1038/s44360-026-00091-4 [50 mcg/g, 100% healthy brains, 99.4% diseased brains, surface area correlates with tumor proliferation, higher concentration in peritumoural tissue]
METHODOLOGICAL CRITIQUE:
“Challenges in studying microplastics in human brain,” Matters Arising, Nature Medicine, November 2025. DOI: 10.1038/s41591-025-04045-3 [Py-GC/MS lipid interference concern, Prof. Oliver Jones]
Science Media Centre expert reactions to Nihart study, February 2025. [Prof. Oliver Jones: “The brain is mainly made of fat, and fats can yield the same pyrolysis products as polyethylene.”]
GOVERNMENT RESPONSE:
ARPA-H/HHS, “STOMP: Systematic Targeting Of MicroPlastics,” April 2, 2026. HHS.gov press release. [”We don’t have a precise way to measure microplastics in our organs”; $144 million program; Director Alicia Jackson quote on measurement gap]
EPA, Drinking Water Contaminant Candidate List addition of microplastics, April 2026.
Fox News / multiple outlets: RFK Jr. and EPA Administrator Zeldin joint announcement, April 2, 2026.
DISEASE CORRELATIONS:
npj Parkinson’s Disease review (2026, Gannan Medical University / Guangzhou Medical University): 100+ studies, MNP contributions to Parkinson’s increase, alpha-synuclein misfolding mechanism. DOI: 10.1038/s41531-026-01272-4
Open Access Government, April 2026 (Pamela J. Lein): “Are micro- and nanoplastics accumulating in the brain promoting neurological dysfunction and disease?” [Parkinson’s doubled in 25 years; 30x concentration in brain vs liver/kidney]
MEDIA COVERAGE:
The Cool Down / Yahoo News, April 23, 2026: “Microplastics found in 100% of brains, but far less than RFK Jr. claim.” [50 mcg/g figure; “100 times less” framing]
The New Lede, February 2025: Campen quote; dementia 3-5x enrichment detail.
National Geographic, May 2025: Carney Almroth quote on BBB and “yet there they are.”
Karmactive, April 2026: 350+ study review by Plastic Soup Foundation; STOMP program details; EPA watchlist addition.